# A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

> **NCT01527383** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 354 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** V212
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01527383
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-21
- **Primary completion:** 2013-02-26
- **Final completion:** 2013-02-26
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527383, "A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT01527383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*